Last update July 15, 2022

ファモチジン

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

H2-type histamine receptor antagonist with similar action than cimetidine. Indicated in the treatment of gastric and/or duodenal ulcer and gastroesophageal reflux disease. oral or intravenous administration.

It is excreted in breast milk in clinically non-significant amount, much less than the dose administered to newborns and infants with gastroesophageal reflux disorders. (Wang 2011, Courtney 1988)

It is used in Pediatrics, even in small infants. (Orenstein 2003)

Although it does not affect prolactin secretion (Corinaldesi 1987, Chremos1986, Smith 1985), there have been several cases of galactorrhea; still unknown whether it is due to Famotidine itself or to gastroesophageal reflux. (Güven 1995, Delpre 1993)

Famotidine and Nizatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation. (Rowe 2013, Nice 2000, Hagemann 1998, Lee 1993)

Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Anderson 2020, Briggs 2015, Schaefer 2015, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000, Lee 1993)

Alternatives

We do not have alternatives for ファモチジン since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

ファモチジン is Famotidine in Japanese.

Is written in other languages:

Tradenames

Main tradenames from several countries containing ファモチジン in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 40 - 45 %
Molecular weight 351 daltons
Protein Binding 15 - 20 %
VD 1.0 - 1.3 l/Kg
pKa 9.29 -
Tmax 1 - 3 hours
3 - 4 hours
M/P ratio 0.4 - 1.8 -
Theoretical Dose 0.008 - 0.01 mg/Kg/d
Relative Dose 1.2 - 1.5 %
Ped.Relat.Dose 0.5 - 1 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on March 17, 2022 Full text (link to original source)
  2. Anderson PO. Antivirals for COVID-19 and Breastfeeding. Breastfeed Med. 2020 Oct;15(10):605-607. Abstract
  3. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  4. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  5. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  6. Wang X, Zhan Y, Hankins GD, Ahmed MS, Rytting, E, Patrikeeva S, Nanovskaya T, Clark S, Jackson A, Venkataramanan R, Caritis S. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol. 2011;204(1) Suppl:S72–3
  7. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  8. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005 Nov 1;22(9):749-57. Review. Abstract Full text (in our servers)
  9. Orenstein SR, Shalaby TM, Devandry SN, Liacouras CA, Czinn SJ, Dice JE, Simon TJ, Ahrens SP, Stauffer LA. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003 Abstract Full text (in our servers)
  10. Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact. 2000 Nov;16(4):319-31. Review. Erratum in: J Hum Lact 2001 Feb;17(1):90. Abstract
  11. Hagemann TM. Gastrointestinal medications and breastfeeding. J Hum Lact. 1998 Sep;14(3):259-62. Review. Abstract
  12. Turton DB, Shakir KM. Galactorrhea caused by esophagitis. Am J Obstet Gynecol. 1995 Abstract
  13. Güven K, Kelestimur F. Hyperprolactinemia and galactorrhea with standard-dose famotidine therapy. Ann Pharmacother. 1995 Abstract
  14. Lee JJ, Rubin AP. Breast feeding and anaesthesia. Anaesthesia. 1993 Jul;48(7):616-25. Review. Abstract Full text (link to original source) Full text (in our servers)
  15. Delpre G, Lapidot M, Lipchitz A, Livni E, Kadish U. Hyperprolactinaemia during famotidine therapy. Lancet. 1993 Abstract
  16. Courtney TP, Shaw RW, Cedar E, Mann SG, Kelly JG. (Proceedings of the BPS, 6-8 July 1988). Excretion of famotidine in breast milk. Br J Clin Pharmacol 26:639P, (poster). 1988 Full text (link to original source) Full text (in our servers)
  17. Corinaldesi R, Pasquali R, Paternico A, Stanghellini V, Paparo GF, Ricci Maccarini M, Barbara L. Effects of short- and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones. Drugs Exp Clin Res. 1987 Abstract
  18. Chremos AN. Pharmacodynamics of famotidine in humans. Am J Med. 1986 Abstract
  19. Smith JL. Clinical pharmacology of famotidine. Digestion. 1985;32 Suppl 1:15-23. Abstract

Total visits

2,124

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM